Announcements Trials
Browse Landscape

Phase

Phase 2 3Phase 3 1

Status

Withdrawn 3Terminated 1Completed 1Active not recruiting 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 4Observational 2

Sponsor

Cancer Type

Endocrine 7NET 6Gastrointestinal 3

Conditions

Neuroendocrine Tumors 6Serotonin Syndrome 2Pancreatic Neoplasms 1Neoplasms 1Diarrhea 1Carcinoid Tumor 1Cachexia 1

Interventions

lutetium Lu 177 dotatate 48Everolimus 40Magnetic Resonance Spectroscopy 21lanreotide 17Temozolomide 17gallium Ga 68 dotatate 15Octreotide 15pembrolizumab 13Nivolumab 13surufatinib 12Capecitabine 12cabozantinib 11177Lu-octreotide, DOTA(0)-Tyr(3)- 11Sunitinib 10pasireotide 9Specimen Handling 9Positron Emission Tomography Computed Tomography 9Lutetium-177 93-Iodobenzylguanidine 9Ga(III)-DOTATOC 8Carboplatin 8telotristat ethyl 6copper dotatate CU-64 6amino-acid, glucose, and electrolyte solution 6Somatostatin 6Ipilimumab 6Fluorodeoxyglucose F18 6Etoposide 6Cisplatin 690Y-octreotide, DOTA-Tyr(3)- 6

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
telotristat ethyl × NET × Clear all
NCT04810091 2026-03-09

Telotristat Ethyl for the Treatment of Carcinoid Heart Disease in Patients With Metastatic Neuroendocrine Tumor

M.D. Anderson Cancer Center

Phase 3 Active not recruiting
79 enrolled 24 charts
EndocrineNET

Neuroendocrine Tumors

NCT03223428 2024-07-24

RELAX

TerSera Therapeutics LLC

Completed
223 enrolled 16 charts
EndocrineNET

Neuroendocrine Tumors, Serotonin Syndrome

NCT04543955 2023-06-27

Telotristat With Lutathera in Neuroendocrine Tumors

University of Kentucky

Phase 2 Terminated
1 enrolled 4 charts
EndocrineNET

Neuroendocrine Tumors

NCT04713202 2023-02-10

NET-PACS

Big Ten Cancer Research Consortium

Phase 2 Withdrawn
EndocrineNET

Diarrhea, Neuroendocrine Tumors, Serotonin Syndrome

NCT04672876 2021-12-17

Telotristat Ethyl for Reducing Intraoperative Carcinoid Crisis in Patients With Neuroendocrine Tumors

University of Chicago

Phase 2 Withdrawn
EndocrineNET

Carcinoid Tumor, Neuroendocrine Tumors

NCT04034745 2020-12-30

Open Label Study to Analyze the Effect of Telotristat Ethyl on Weight Regulation/Gain

Cedars-Sinai Medical Center

Withdrawn
EndocrineGastrointestinalNET

Cachexia, Neoplasms, Pancreatic Neoplasms, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡